Contact

“Antimicrobial resistance, I do believe, is the existential threat of this century.”
Admiral Brett P. Giroir, U.S. assistant secretary for health; Pew online, July 27, 2020

EVŌQ Bio provides additional weapons in the world’s war against superbugs and protects the storehouse of last resort antimicrobials. Our antimicrobial therapeutic demonstrates efficacy against the worst of the world’s antibiotic resistant bacteria. Our uniquely elegant mechanism of action provides a biotechnology platform to create precise novel product outcomes for numerous applications and allows for multiple drug administration pathways.

Our key ingredient for an inhaled respiratory therapeutic—our primary focus—is now in its late-stage pre-clinical phase as we initiate our FDA path. Pre-clinical studies indicate our nanomaterials are non-toxic to lung epithelial cells and penetrate lung sputum to kill bacteria, rivaling tobramycin as a therapeutic. Furthermore, in vitro testing shows no development of compound resistance to our nanomaterials, demonstrating efficacy up to 21 days.

EVŌQ Bio nanoparticles permeate biofilm, a protective environment for bacteria. Biofilm allows bacteria to thrive and become drug-resistant in a way that changes the physical nature of the biofilm, thus further protecting the bacteria.

Our Pipeline

Pulmonary infections

Indication Targets Drug/Therapeutic Candidate
    Discovery IND-Enabling Early Clinical
Cystic Fibrosis Burkholderia cenocepacia Pseudomonas aeruginosa Stenotrophomonas
Late-stage pre-clinical
Late-stage pre-clinical
EVQ-218
   
Bacterial Pneumonia Streptococcus pneumoniae Staphylococcus aureus Streptococcus pyogenes Klebsiella pneumoniae Haemophilus influenzae
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-218
   
Pulmonary Fungal Infections Candida albicans Aspergillus
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-218
   
Tuberculosis Mycobacterium tuberculosis
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-218
   

Topical Infections

Indication Targets Drug/Therapeutic Candidate
    Discovery IND-Enabling Early Clinical
Cellulitis Group A β-hemolytic streptococcus Streptococcus pneumoniae
Late-stage pre-clinical
Late-stage pre-clinical
EVQ-221
   
Staph Skin Infections (e.g. MRSA) Methicillin-resistant Staphylococcus aureus
Early-stage pre-clinical
Early-stage pre-clinical
EVQ-221
   

Contact Us

Interested in learning more or partnering with us? Let’s connect!